Get started
Author

Sha Huang

ORCID: 0000-0002-0343-3210
Observed ORCID: 0000-0002-0343-3210
OpenAlex ID: A5111323570
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
2023 · Pier Luigi Zinzani, Jiří Mayer, et al. · Journal of Clinical Oncology · 106
PDF
Antiviral Medications for Treatment of Nonsevere Influenza
2025 · Ya Gao, Yunli Zhao, et al. · JAMA Internal Medicine · 43
Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study
2023 · Emmanuel Bachy, Kerry J. Savage, et al. · Blood Advances · 24
PDF
Flexible intelligent sensing patches for augmented tactile and thermal perception
2025 · Ruilai Wei, Junling Zhang, et al. · Science China Materials · 14
Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: Results from a phase 2 study.
2022 · Emmanuel Bachy, Kerry J. Savage, et al. · Journal of Clinical Oncology · 7
MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.
2023 · Loretta J. Nastoupil, Yuqin Song, et al. · Journal of Clinical Oncology · 6
Effectiveness of the frailty index in predicting recurrent pneumonia and death in long-term hospitalized patients with vascular cognitive impairment
2024 · Rong Zheng, Sha Huang, et al. · Experimental Gerontology · 3
Effectiveness of the frailty index in predicting short-term and long-term mortality risk in patients with chronic heart failure
2024 · Xia Lin, Sha Huang, et al. · Archives of Gerontology and Geriatrics · 2
Antivirals for treatment of non-severe influenza: a systematic review and network meta-analysis of randomized controlled trials
2024 · Ya Gao, Yunli Zhao, et al. · medRxiv · 2
PDF
Final analysis of the randomized phase 2 ROSEWOOD study of zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refractory follicular lymphoma
2025 · Pier Luigi Zinzani, Jiri Mayer, et al. · Blood · 1
Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: Updated analysis of the ROSEWOOD study.
2023 · Christopher Flowers, Pier Luigi Zinzani, et al. · Journal of Clinical Oncology · 1
Phase 1 study of zanubrutinib plus lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma
2026 · Zheng Song, Ying Cheng, et al. · Blood Advances
PDF
Application of Super‐Resolution Microscopy in Virology Research: Principles, Technological Advances, and Analysis of the Viral Life Cycle
2025 · Mengyi Liu, Luhao Zhang, et al. · Journal of Biophotonics
PDF
P1080: Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab in Patients With Relapsed/refractory Follicular Lymphoma: Updated Analysis of the Rosewood Study
2023 · Judith Trotman, Pier Luigi Zinzani, et al. · HemaSphere
Works count: 14
Citation count: 209
H-index: 6
I10-index: 4
Year
Topic
Type